Benzinga | Oct 14, 2020 07:02AM EDT

FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined

Late-breaking abstracts explore cardiovascular outcomes of patients with anemia in chronic kidney disease (CKD) treated with roxadustat, including associations with achieved hemoglobin levels and risk of Major Adverse Cardiovascular Events (MACE) and MACE+

New analyses evaluate efficacy of roxadustat across the continuum of patients with anemia in CKD -- both on dialysis and not on dialysis -- including different dialysis modalities, iron repletion status, and comorbidities.

Presentations address safety profile of roxadustat related to neoplasms, hypertension, and ophthalmological effects

Additional presentations explore increased risk of red blood cell transfusion at lower hemoglobin levels and impact of roxadustat on rates of hospitalization due to congestive heart failure